Heart Rhythm
Volume 7, Issue 1 , Pages 9-14 , January 2010

Incidence and predictors of mortality following ablation of ventricular tachycardia in patients with an implantable cardioverter-defibrillator

  • William H. Sauer, MD, FHRS

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Colorado, Aurora, Colorado
    • ,
  • Erica Zado, PA-C

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
    • ,
  • Edward P. Gerstenfeld, MD

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
    • ,
  • Francis E. Marchlinski, MD, FHRS

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
    • ,
  • David J. Callans, MD, FHRS

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
    • Corresponding Author InformationAddress reprint requests and correspondence: Dr. David J. Callans, Section of Cardiac Electrophysiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania 19104

Received 10 July 2009 ,Accepted 7 September 2009.

References 

  1. Segal OR, Chow AW, Markides V, Schilling RJ, Peters NS, Davies DW. Long-term results after ablation of infarct-related ventricular tachycardia. Heart Rhythm. 2005;2:474–482
  2. O'Donnell D, Bourke JP, Anilkumar R, Simeonidou E, Furniss SS. Radiofrequency ablation for post infarction ventricular tachycardia (Report of a single centre experience of 112 cases). Eur Heart J. 2002;23:1699–1705
  3. O'Callaghan PA, Poloniecki J, Sosa-Suarez G, Ruskin JN, McGovern BA, Garan H. Long-term clinical outcome of patients with prior myocardial infarction after palliative radiofrequency catheter ablation for frequent ventricular tachycardia. Am J Cardiol. 2001;87:975–979
  4. Stevenson W, Wilber D, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction. Circulation. 2008;118:2773–2782
  5. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000;101:1288–1296
  6. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  7. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  8. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583
  9. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–754
  10. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–1302
  11. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–678
  12. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65–75
  13. Rothman SA, Hsia HH, Cossu SF, Chmielewski IL, Buxton AE, Miller JM. Radiofrequency catheter ablation of postinfarction ventricular tachycardia: long-term success and the significance of inducible nonclinical arrhythmias. Circulation. 1997;96:3499–3508
  14. Stevenson WG, Friedman PL, Kocovic D, Sager PT, Saxon LA, Pavri B. Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation. 1998;98:308–314
  15. Calkins H, Epstein A, Packer D, et al. Cooled RF Multi Center Investigators Group Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol. 2000;35:1905–1914
  16. Borger van der Burg AE, de Groot NM, van Erven L, Bootsma M, van der Wall EE, Schalij MJ. Long-term follow-up after radiofrequency catheter ablation of ventricular tachycardia: a successful approach?. J Cardiovasc Electrophysiol. 2002;13:417–423
  17. Soejima K, Delacretaz E, Suzuki M, et al. Saline-cooled versus standard radiofrequency catheter ablation for infarct-related ventricular tachycardias. Circulation. 2001;103:1858–1862
  18. Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation. 2001;104:664–669
  19. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  20. Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol. 2002;39:1323–1328
  21. O'Donnell D, Bourke JP, Furniss SS. Standardized stimulation protocol to predict the long-term success of radiofrequency ablation of postinfarction ventricular tachycardia. Pacing Clin Electrophysiol. 2003;26(1 Pt II):348–351

 Drs. Marchlinski, Callans, and Gerstenfeld have received research funding support from St. Jude Medical and Biosense-Webster, Inc., manufacturers of ablation and mapping equipment. Drs. Marchlinski and Callans have received honoraria from Biosense-Webster.

PII: S1547-5271(09)01001-7

doi: 10.1016/j.hrthm.2009.09.014

Heart Rhythm
Volume 7, Issue 1 , Pages 9-14 , January 2010

Article Tools

* Image Usage & Resolution